nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—ADRB1—Monoamine GPCRs—DRD4—conduct disorder	0.0783	0.0783	CbGpPWpGaD
Metipranolol—ADRB2—Monoamine GPCRs—DRD4—conduct disorder	0.0766	0.0766	CbGpPWpGaD
Metipranolol—ADRB1—Melatonin metabolism and effects—MAOA—conduct disorder	0.0695	0.0695	CbGpPWpGaD
Metipranolol—ADRB1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0658	0.0658	CbGpPWpGaD
Metipranolol—ADRB2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0644	0.0644	CbGpPWpGaD
Metipranolol—ADRB1—Monoamine GPCRs—HTR2A—conduct disorder	0.0511	0.0511	CbGpPWpGaD
Metipranolol—ADRB2—Monoamine GPCRs—HTR2A—conduct disorder	0.05	0.05	CbGpPWpGaD
Metipranolol—ADRB1—G alpha (s) signalling events—CGA—conduct disorder	0.0485	0.0485	CbGpPWpGaD
Metipranolol—ADRB2—G alpha (s) signalling events—CGA—conduct disorder	0.0474	0.0474	CbGpPWpGaD
Metipranolol—ADRB1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0429	0.0429	CbGpPWpGaD
Metipranolol—ADRB2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.042	0.042	CbGpPWpGaD
Metipranolol—ADRB2—GPCRs, Other—DRD4—conduct disorder	0.034	0.034	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0231	0.0231	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0226	0.0226	CbGpPWpGaD
Metipranolol—ADRB2—GPCRs, Other—HTR2A—conduct disorder	0.0222	0.0222	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CGA—conduct disorder	0.0176	0.0176	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CGA—conduct disorder	0.0172	0.0172	CbGpPWpGaD
Metipranolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0151	0.0151	CbGpPWpGaD
Metipranolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0148	0.0148	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0129	0.0129	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0127	0.0127	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CGA—conduct disorder	0.00994	0.00994	CbGpPWpGaD
Metipranolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00986	0.00986	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—DRD4—conduct disorder	0.00985	0.00985	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CGA—conduct disorder	0.00973	0.00973	CbGpPWpGaD
Metipranolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00964	0.00964	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—DRD4—conduct disorder	0.00964	0.00964	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CGA—conduct disorder	0.00903	0.00903	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CGA—conduct disorder	0.00883	0.00883	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00844	0.00844	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00826	0.00826	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—HTR2A—conduct disorder	0.00643	0.00643	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—HTR2A—conduct disorder	0.00629	0.00629	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—DRD4—conduct disorder	0.00557	0.00557	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—DRD4—conduct disorder	0.00545	0.00545	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CGA—conduct disorder	0.00533	0.00533	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CGA—conduct disorder	0.00522	0.00522	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—DRD4—conduct disorder	0.00506	0.00506	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—DRD4—conduct disorder	0.00495	0.00495	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—WASF1—conduct disorder	0.00428	0.00428	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—WASF1—conduct disorder	0.00418	0.00418	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—HTR2A—conduct disorder	0.00363	0.00363	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—HTR2A—conduct disorder	0.00355	0.00355	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—HTR2A—conduct disorder	0.0033	0.0033	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—HTR2A—conduct disorder	0.00323	0.00323	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—DRD4—conduct disorder	0.00299	0.00299	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—DRD4—conduct disorder	0.00292	0.00292	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HTR2A—conduct disorder	0.00195	0.00195	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HTR2A—conduct disorder	0.00191	0.00191	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EP300—conduct disorder	0.00103	0.00103	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EP300—conduct disorder	0.00101	0.00101	CbGpPWpGaD
